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Abstract
Background: Multiple myeloma is a cancer of antibody producing plasma cells whose etiology is
unknown. FGF signaling has been implicated in myeloma pathogenesis but its precise role remains
unclear.
Results: Here, we investigate the biochemical and phenotypic consequences of FGF stimulation in
several different human myeloma cell lines. We find that FGF signaling inhibits cell cycle progression
in two lines and surprisingly, reduces the expression of c-myc while turning on c-fos. In several
other lines, FGF signaling does not affect proliferation rate, including cells harboring translocated
FGF Receptor 3. When cells are presented with a growth arrest signal, FGF addition induces cell
death.
Conclusions:  By showing that FGF signaling inhibits mitogenesis and induces apoptosis, we
demonstrate novel effects of activating this ubiquitous signaling pathway in multiple myeloma.
Background
Fibroblast growth factor (FGF) signaling regulates the
activity of virtually all higher vertebrate cell types. In addi-
tion to controlling normal development and physiology,
numerous observations support the concept that FGF sig-
naling is abnormal in most forms of human cancer. A
review of this voluminous literature is not possible here,
but it should be noted that in many cases FGF signaling
inhibits rather than promotes growth of the transformed
clone. For example, FGF2 (basic FGF) slows the prolifera-
tion of breast cancer cells [1,2], and low levels of FGF2 are
associated with accelerated breast cancer progression and
worse prognosis [3]. Similarly, mutations in FGF Receptor
3 (FGFR3) are strongly associated with less aggressive
forms of bladder cancer, suggesting that FGF signaling
may inhibit proliferation in this malignancy [4,5]. Finally,
recent studies show that FGF2 induces apoptosis in
Ewing's sarcoma cells [6].
Alternatively, in some human cancer models, FGF signal-
ing has no effect on tumor progression. In the SV40 T anti-
gen transgenic model of pancreatic cancer, rigorous
genetic analysis using both gain and loss of function alle-
les of FGF Receptor 4 has demonstrated that FGFR4 has no
effect on the growth of transformed islet cells, even
though it is invariably expressed in this setting [7]. This
finding implies that the defect in cell fate determination
seen in cancer is accompanied by the misexpression of
genes whose action is neutral with respect to oncogenesis.
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Multiple Myeloma (MM) is a neoplasia of transformed
plasma cells [8]. Genetic abnormalities, including chro-
mosomal translocations, inversions, and deletions are a
common feature of MM [9]. Some of the translocations
have been characterized and the genes within the rear-
ranged loci pinpointed. One such translocation is t (4;14)
which harbors at least two genes in the displaced interval:
Fibroblast Growth Factor Receptor 3 (FGFR3) and Multi-
ple Myeloma Set Protein (MMSET) [10,11]. The presence
of FGFR3 in the translocated region has led to the pro-
posal that FGF signaling promotes oncogenesis in mye-
loma [12].
The effect of activating FGF signaling on MM cell prolifer-
ation is unclear. The translocation involving FGFR3 is
observed infrequently, being detectable in approximately
fifteen percent of patients [11,13-16]. In addition, activat-
ing mutations in regulatory domains of FGFR3 have been
observed in multiple myeloma cell lines and rarely in
patient samples [14,17]. These mutations generally have
been shown to augment the signaling potential of the
receptor. Interestingly, recent microarray analysis reveals
that FGFR3 mRNA is associated with gene expression pat-
terns seen in early, less aggressive sub-groups of multiple
myeloma [18]. Indeed, FGFR3 mRNA expression was
never observed in more advanced stages of the disease
despite translocation of the FGFR3 genomic locus to the
IgH gene. This observation indicates that expression of
FGFR3 mRNA is disfavored during disease progression.
Outcome analysis shows no substantial difference in the
progression of patients with translocated FGFR3 [15].
Notably, multiple FGF receptors are expressed in both
myeloma patient samples and cell lines [19,20], suggest-
ing that genes in this family other than FGFR3 are impor-
tant. Although multiple myeloma likely originates from
an activated, post-switch B lymphocyte, little data exists
on the expression of FGF receptors in mature B cells. One
exception is the demonstration that FGF receptor stimula-
tion controls the proliferation of activated normal human
peripheral blood B cells [21]. Consistent with a role for
FGF signaling in mature B cells, we have found that FGF
deficient mice produce more antibody to a Type 1 inde-
pendent antigen and conversely, antibody production is
suppressed in FGF over-expressing mice (manuscript in
preparation). Thus, it is likely that FGF receptors play a
role in mature B cell function. Finally, in addition to mul-
tiple receptors, several different FGF ligands are expressed
in patient samples and cell lines. For example, FGF2
expression is higher in the serum of patients with multiple
myeloma as compared to controls [22] and this difference
is even larger when bone marrow levels are compared
[23]. Recent experiments suggest that one source of the
FGF2 may be the myeloma cells themselves [20].
Here we examine the role of FGF signaling in human mul-
tiple myeloma cell lines. We find that stimulation of the
FGF pathway either inhibits growth or has no effect
despite the presence of translocated FGFR3. Growth inhi-
bition is accompanied by reduced expression of c-myc.
Surprisingly, FGF treatment of cells in low serum medium
stimulates cell death.
Results
To determine whether FGF could influence myeloma cell
proliferation, we incubated myeloma lines with FGF1
under various conditions. Although similar results were
obtained with FGF2, we performed most experiments
with FGF1 since it stimulates the widest number of recep-
tors [24]. We assayed growth rate in lines containing
translocated FGFR3, such as OPM1, OPM2, JIM3, KMS11,
H929, UTMC2, and KMS18 and also in lines lacking this
abnormality. In both the OPM2 and OPM1 cell lines, FGF
signaling reduced cell number during log phase growth,
whereas in the other cell lines it had no effect (Fig. 1a).
Since OPM1 and OPM2 cells are derived from the same
patient [25], FGF signaling may slow cell proliferation in
situ, since a reversal of the signaling pathway would be
unlikely to take place upon adaptation to culture in two
different cases. These cells express an FGFR3 mutant,
K650E, which has significantly enhanced tyrosine kinase
activity [26]. In an Interleukin-6 dependent mouse plas-
macytoma line constitutively expressing elevated levels of
FGFR3 (B9 cells), FGF1 had no effect on cell number (fig.
1a). In addition, no effect was observed in a plasmacy-
toma variant expressing the hyperactive mutant K650E.
Previously, it had been reported that polyclonal popula-
tions expressing high levels of the K650E allele proliferate
more rapidly compared to polyclonal populations lacking
this receptor [27]. While we do not know the precise rea-
son for the discrepancy, this study examined the effects of
FGF treatment during apoptosis as a consequence of Il-6
withdrawal.
To investigate how FGF signaling influences cell cycle pro-
gression, we examined the cell cycle profile by FACS anal-
ysis of DNA content. We observed that progression
through all phases of the cell cycle is retarded by treatment
with FGF1, as reflected by a shift to the left in the number
of cells with a given fluorescence intensity (Fig. 1b). We
found three-fold fewer cells in the G2-M phase of the cell
cycle after three days in the presence of FGF1 (region A,
fig. 1b). These data demonstrate that FGF signaling slows
cell cycle progression in human myeloma cells.
The c-MYC oncoprotein is frequently dysregulated in
human cancer and c-myc plays a central role in the growth
and proliferation of lymphocytes, including mature B
cells [28]. Moreover, irregularities at the c-myc locus have
been documented in virtually all human myeloma cellBMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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lines [29]. In OPM2 cells, c-myc is translocated to the IgH
locus [30], suggesting that its expression may be deregu-
lated. To determine whether c-myc expression is affected
by FGF stimulation in myeloma cells, we examined the
levels of c-myc mRNA and protein following addition of
FGF1. While in some cell types, growth factor addition
enhances c-MYC expression, FGF1 stimulation down-reg-
ulated c-MYC in OPM2 cells (fig. 2a). To our knowledge,
this represents the first example of a decrease in c-MYC
expression in response to a classical tyrosine kinase
growth factor. The decrease in c-MYC protein levels may
be a result of decreased levels of the mRNA which was also
lower in the presence of FGF 1 (fig. 2b). We note that
decreased c-myc mRNA expression is only observed at con-
centrations of FGF1 greater than 1 ng/ml.
Why is there no effect on proliferation rate in cell lines
harboring translocated FGFR3? The FGF signal transduc-
tion pathway could be stimulated in these lines but the
stimulation could fail to reduce cell number due to ineffi-
cient or defective inhibition of the DNA synthesis machin-
ery. To determine whether FGF signaling affects DNA
synthesis, we incubated cells with FGF1 and assayed H3
thymidine incorporation into DNA. We found that FGF1
treatment either modestly inhibited DNA synthesis or had
no effect in cell lines containing the 4;14 translocation
(Fig. 3). Despite the relatively slow growth rate of mye-
loma cell lines, the decrease in DNA synthesis in OPM2
cells was observable twenty four hours after growth factor
addition.
FGF Signaling Either Inhibits Myeloma Cell Proliferation or Has No Effect Figure 1
FGF Signaling Either Inhibits Myeloma Cell Proliferation or Has No Effect. A) Myeloma cell lines were treated with 
FGF1 (100 ng/ml) and heparin (10 ug/ml) or heparin alone (control) for three days and cell number was determined. B9 cells 
are a mouse plasmacytoma line stably expressing FGF Receptor 3 wild type (wt) or hyperactive mutant K650E [27]. Error bars 
represent standard deviation of assays performed in triplicate. Results shown are representative of more than four independ-
ent determinations for OPM2 cells and three independent determinations for OPM1 cells; p < .01, Student's paired t test. B) 
OPM1 and OPM2 cells were treated with FGF1 (10 ng/ml) and heparin (10 ug/ml) or heparin only for three days and DNA 
content was measured using FACS analysis of ethidium bromide stained nuclei.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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One of the earliest transcriptional events in response to
FGF signaling is the induction of c-fos. To determine the
effect of FGF signaling on c-fos expression, we examined
the levels of c-fos mRNA after FGF stimulation of serum
starved cells. The cell lines OPM2, KMS11, and UTMC2 all
strongly activated c-fos transcription in response to FGF2
(Fig. 4). These lines carry the 4;14 translocation. We con-
clude that early nuclear events in response to FGF stimu-
lation are properly activated in myeloma cell lines whose
proliferation rate is unchanged by FGF stimulation (Fig.
1). In addition, these results have significant implications
for models of FGFR3 function. Hyperactive mutant forms
of FGFR3 are thought to be constitutively active and lig-
and independent. Experiments with KMS11 and OPM2
cells have shown that basal auto-phosphorylation of
FGFR3 and MAP kinase activity are higher under serum
starved conditions, suggesting that FGF signaling is
persistently active in these cells [16]. We find that FGFR3
mutants respond strongly to ligand and with respect to
nuclear signaling events, are not constitutively activated.
Therefore, activating mutations in a cell surface receptor
in the absence of ligand do not necessarily lead to the
expected changes in gene expression from stimulation of
the receptor's signal transduction pathway.
Since it is possible that FGF signaling could influence sur-
vival without affecting proliferation rate, we explored
whether it could modulate either serum starvation or dex-
amethasone-induced cell death. FGF stimulation did not
protect myeloma cell lines from either death inducing
stimulus whereas IL-6 did inhibit cell death under the
same conditions (Fig. 5A,5B). While we did not directly
FGF Signaling Inhibits c-myc expression Figure 2
FGF Signaling Inhibits c-myc expression. A) Immunoblot of RIPA lysates from OPM2 cells using monoclonal anti-c-MYC 
antibody. Cells were treated with FGF1 (or Osteoprotegerin as negative control) for 24 or 48 hours at the indicated concen-
trations. Cells were harvested in RIPA lysis buffer containing protease inhibitors. B) Expression of c-myc mRNA levels. Cells 
were treated with FGF1 at the indicated concentrations for 3 days and c-myc mRNA levels were measured by Northern blot. 
Bottom panel shows ethidium bromide stained 18S ribosomal RNA.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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measure apoptosis in these lines, others have shown that
dexamethasone and serum starvation activate an
apoptotic program in these cells [31,32]. Unexpectedly,
we observed that FGF1 induces apoptosis in OPM2 cells.
When these cells are cultured in reduced serum, FGF1 pro-
duced a dose-dependent acceleration of apoptosis, lead-
ing to a three-fold increase in sub G0 DNA content 24
hours after transfer to serum free conditions (Fig. 5C).
This effect is accompanied by reduced DNA synthesis, as
reflected by a shift to the left in the number of cells with a
given DNA content. Consequently, FGF signaling slows
cell cycle progression during serum starvation, demon-
strating that cell death is not a result of a conflict between
the growth arrest signal from serum starvation and a puta-
tive growth stimulatory signal from FGF1.
Discussion
We have investigated the role of FGF signaling in human
multiple myeloma cell lines. Examination of numerous
lines reveals that FGF treatment either reduces cell
number or has no effect. Moreover, when OPM2 cells are
presented with a strong growth arrest signal by culturing
in low serum medium, FGF addition stimulates apoptosis.
These studies demonstrate that the function of FGF sign-
aling in multiple myeloma is more complex than previ-
ously appreciated. Since reduced proliferation is observed
in two different cell lines derived from the same patient,
FGF signaling may inhibit mitogenesis in vivo and thus
retard disease progression. This hypothesis is consistent
with the silencing of FGFR3 mRNA expression in
advanced myeloma, even though the FGFR3 locus is
translocated to the actively expressed IgH region [18]. In
FGF Signaling Reduces DNA Synthesis in Myeloma Cells Figure 3
FGF Signaling Reduces DNA Synthesis in Myeloma Cells. Myeloma cell lines containing t(4;14) were incubated in 
serum free medium with FGF1 (10 or 100 ng/ml) plus heparin (10 ug/ml) and incorporation of H3 thymidine into DNA was 
measured one day later. Data are expressed as percent of control (heparin only) and represent the mean of five independent 
experiments, measured in triplicate; p < .01 Student's paired t test.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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FGF Signaling Induces fos in Myeloma Cell Lines containing t(4;14) Figure 4
FGF Signaling Induces fos in Myeloma Cell Lines containing t(4;14). Cell lines were cultured in serum free medium 
for twenty four hours and FGF2 (50 ng/ml) or 10% serum was added. Total RNA was isolated and the expression of c-fos was 
measured at the indicated times. Ethidium bromide stain of 28 S RNA is shown.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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FGF Signaling Induces Cell Death in OPM2 Cells Figure 5
FGF Signaling Induces Cell Death in OPM2 Cells. A) RPMI 8226 myeloma cells were cultured in serum free medium for 
24 hours or serum containing medium plus 10 uM dexamethasone (last three columns) in the presence of the indicated factors. 
The number of dead cells was evaluated using trypan blue exclusion two days after dexamethasone treatment. B) FGF signaling 
does not protect ARP-1 myeloma cells from dexamethasone-induced apoptosis. Conditions as in panel A. Pre-treatment con-
sisted of pre-incubation of the cells with IL-6 for one hour, followed by death inducer. C) OPM2 cells were cultured in serum 
free medium for one day in the presence or absence of FGF1 and cell cycle analysis of ethidium bromide stained nuclei was 
performed. Results are representative of four independent determinations; p < .01 Student's paired t test. Red trace shows 
results with 100 ng/ml FGF1 as compared to heparin only (blue trace). Inset shows quantification of sub G0 DNA content for 
10 and 100 ng/ml FGF1 as compared to heparin alone and a magnified version of the sub G0 region shown in the FACS.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
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addition, since FGF fails to inhibit proliferation in most
myeloma cell lines despite expression of other FGF recep-
tors [19,20], FGF-induced growth inhibition may need to
be silenced for the transformed clone to expand. Since
most myeloma cell lines are derived from cells which have
escaped the bone marrow, we speculate that FGF signaling
may serve to inhibit proliferation in early stages of the dis-
ease, when the transformed clone is confined to the bone
marrow microenvironment. Although we can not exclude
the possibility that FGF signaling may stimulate prolifera-
tion in multiple myeloma cells at some stage of their
development, our data indicate that no effect or slower
proliferation are more likely outcomes. Studies with pri-
mary myeloma cells may shed further light on this issue.
We find that FGF-induced growth inhibition is accompa-
nied by reduced c-MYC expression. To our knowledge,
this is the first demonstration of a reduction in c-MYC
expression by a classical tyrosine kinase growth factor
since FGF stimulation has the opposite effect in many
other cell types. Aberrations at the c-myc locus are almost
always observed in multiple myeloma cell lines, implying
that cis-deregulation is required for growth. In OPM2
cells, the c-myc gene is fused to the IgH locus [30]. Despite
this abnormality, it is surprising to observe that FGF
stimulation overcomes whatever destabilizing effect it
introduces and suppresses c-MYC expression. While acti-
vation of the c-myc pathway may not be an initiating event
in multiple myeloma, numerous studies have revealed
that c-myc contributes to many different human cancers,
including multiple myeloma. Therefore, signals which
counteract c-MYC expression are of paramount
importance.
Studies of the effect of activating the FGFR3 pathway in
both fibroblasts and hematopoietic cells have shown that
FGFR3 poorly stimulates proliferation. For example,
despite abundant expression, both wild type and hyperac-
tive mutant alleles of FGFR3 were unable to transform
NIH 3T3 cells [33]. In another study, only the K650E
allele produced tumors in nude mice while the wild-type
receptor was inert [17]. Recently, a novel FGFR3 mutation
(G380D) was shown to weakly transform NIH 3T3 cells.
This mutant displayed a similar potency to the K650E
allele and was more than 300 times less active than the
standard receptor tyrosine kinase/oncogene trk [16]. In
BaF3 pro B cells, overexpression of FGFR1 stimulates DNA
synthesis while overexpression of FGFR3 does not
[24,26].
On the other hand, the K650E allele has been shown to
induce pre-B cell tumors when retrovirally expressed in
the bone marrow of transgenic mice [34]. While this is the
strongest evidence to date that FGFR3 can positively affect
proliferation in hematopoietic cells, over-expression
experiments using retroviral vectors which are not easily
down regulated might best be interpreted with caution.
Indeed, the very early pre-B cell phenotype of the tumors
in this report raise the possibility that FGF signaling may
regulate immature rather than mature B cell proliferation.
Why does FGF have no effect on the rate of cell division of
some myeloma cell lines containing the 4;14
translocation, such as KMS11 and UTMC2? One possibil-
ity is that early steps in signaling are not activated nor-
mally as a result of mutation. For example, previous
studies in plasmacytoma cell lines have demonstrated a
block in TGF beta signaling due to inefficient receptor
binding at the cell surface [35]. Another possibility is that
early steps in FGF signaling are activated but later steps are
blocked. To assay for defects in the signal transduction
pathway, we examined expression of c-fos in response to
FGF stimulation. Since c-fos is normally induced, we con-
clude that the FGF pathway leading to changes in gene
expression remains unperturbed by mutation.
The induction of apoptosis by FGF stimulation in OPM2
cells reveals that in sharp contrast to acting as a survival
factor, FGF signaling transmits a death signal. Death
induction by classical growth and survival factors is not
without precedent. FGF signaling in human chondrocytes
expressing the K650E allele activates cell death without
affecting proliferation rate [36]. Moreover, in FGF2 trans-
genic mice, FGF induced cell death is inhibited by
reducing stat1 gene dosage, suggesting that stat1 mediated
growth inhibition may precede the execution of the
apoptotic program [37]. Notably, FGF stimulation of mul-
tiple myeloma cell lines harboring t(4;14) does not stim-
ulate stat activity [16]. The accumulating evidence for
death induction by receptor tyrosine kinases implies that
further investigation of this phenomenon may reveal new
pathways of cell suicide. Future research will be directed at
understanding in greater detail the molecular mechanism
by which FGF signaling controls these processes.
Conclusion
We have demonstrated that FGF signaling inhibits the
proliferation of human myeloma cells.
Inhibition is accompanied by reduced DNA synthesis and
surprisingly, reduced expression of the proto-oncogene c-
myc. In many other cell lines FGF signaling did not affect
proliferation rate, including cell lines with translocated
FGFR3. Under growth suppressed conditions, FGF signal-
ing induced apoptosis. Taken together, our data reveal
unanticipated effects of FGF signaling in multiple mye-
loma and suggest novel conclusions concerning its role in
the oncogenic process.BMC Cell Biology 2003, 4 http://www.biomedcentral.com/1471-2121/4/17
Page 9 of 10
(page number not for citation purposes)
Methods
Cell Culture
OPM1 cells were from Edward Thompson (University of
Texas). UTMC2, OPM2, KMS11, and JIM3 cells were the
kind gift of P. Leif Bergsagel (Cornell University Medical
College). KMS18 cells were from Antonino Neri (Univer-
sity of Milan), ARP-1 cells were from Joshua Epstein (Uni-
versity of Arkansas), and ANBL6 lines were from Diane
Jelinek (Mayo Clinic). B9 plasmacytoma cells were the
generous gift of A. Keith Stewart (University of Toronto)
and were supplemented with 1–10 ng/ml Il-6. All other
lines were from ATCC. All cell lines were cultured in RPMI
1640 media with 10% FCS, except UTMC2 cells which
were supplemented with 1–10 ng/ml Il-6 (R and D Sys-
tems). For serum starvation experiments, cells were
replated in media lacking serum but containing insulin,
transferrin and selenium (Gibco Serum Supplement) for
twenty four hours. Recombinant human FGF1 and 2 were
from R and D (Minnesota).
Cell Proliferation Experiments
Cell number following FGF stimulation during log phase
growth was determined either by counting the number of
trypan blue negative cells or by Coulter Counter with
identical results. For B9 plasmacytoma derivatives, prolif-
eration rate was measured in the presence of 1–10 ng/ml
Il-6. For thymidine incorporation studies, cells were incu-
bated in serum free medium for 24 hours in the presence
or absence of FGF1. Cells were harvested 24 hours later.
4–16 hours before harvest, 0.5 uCi H3 thymidine per 100
ul was added. Experiments were performed in triplicate
and counted on a Beta plate reader (LKB Wallac).
Cell Cycle Experiments
FACS analysis was performed on nuclei isolated by NP-40
lysis [38]. Briefly, cells were centrifuged at 1000 × G and
incubated in NP-40 lysis buffer with RNAse (10 ug/ml) at
room temperature for 30 minutes followed by citric acid/
sucrose buffer containing ethidium bromide. Successful
isolation of nuclei was confirmed by microscopic exami-
nation. Cell cycle analysis was performed on a Coulter
Model XL flow cytometer, gating on signals indicative of
intact, non-clumped nuclei.
Immunoblotting and Northern analysis
Cells in log phase growth were harvested by centrifugation
and lysed at 4° in RIPA buffer (20 mM Tris pH 8.0, 137
mM NaCl, 10% v/v glycerol, 1% Nonidet P-40, 0.1%
Sodium Dodecyl Sulfate, 0.5% Sodium Deoxycholate, 2
mM EDTA) containing protease inhibitors (aprotinin,
leupeptin, pepstatin and PMSF). Lysates were clarified by
centrifugation at 14, 000 × G. Protein concentration was
determined using the BCA method (Pierce). c-MYC was
visualized by ECL (Amersham) using the monoclonal C-
33 antibody at 1:1000 (Santa Cruz) and HRP coupled
Goat anti-Mouse secondary at 1:10,000 (Jackson).
For studies of fos and myc mRNA expression, total RNA
was isolated by guanidium isothiocyanate lysis (Trizol,
GIBCO/BRL) or Qiagen mRNA easy (Qiagen) and sepa-
rated on 1% agarose gels containing formaldehyde. RNA
was transferred to nylon membranes (Schleicer and
Schuell) and probed with random primer generated P32
labeled probes from gel purified fragments of mouse
cDNA encoding c-fos and c-myc. Washing was performed
at a minimum stringency of 55°C in 0.1X SSC and 0.1%
SDS.
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